Bioventus Inc. raised earnings guidance for the twelve months ending December 31, 2023. For the period, the company now expects net sales to be between $498 million to $505 million, an increase in the midpoint from company's previous guidance of $490 million to $505 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.33 USD | -6.91% | -5.38% | +20.11% |
May. 07 | Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024 | CI |
May. 07 | Transcript : Bioventus Inc., Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.11% | 404M | |
-24.88% | 7.32B | |
+7.04% | 6.66B | |
+15.10% | 5.5B | |
-17.88% | 4.88B | |
+14.96% | 4.1B | |
-20.83% | 3.89B | |
-25.03% | 2.83B | |
+44.01% | 2.31B | |
+2.10% | 2.07B |
- Stock Market
- Equities
- BVS Stock
- News Bioventus Inc.
- Bioventus Inc. Raises Earnings Guidance for the Twelve Months Ending December 31, 2023